Drug Patents owned by Vivus
1. Drug name - QSYMIA
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8895057 | VIVUS | Escalating dosing regimen for effecting weight loss and treating obesity |
Jun, 2028
(5 years from now) | |
| US9011906 | VIVUS | Escalating dosing regimen for effecting weight loss and treating obesity |
Jun, 2028
(5 years from now) | |
| US9011905 | VIVUS | Low dose topiramate/phentermine composition and methods of use thereof |
Jun, 2028
(5 years from now) | |
| US8895058 | VIVUS | Low dose topiramate/phentermine composition and methods of use thereof |
Jun, 2028
(5 years from now) | |
| US8580298 | VIVUS | Low dose topiramate/phentermine composition and methods of use thereof |
May, 2029
(6 years from now) | |
| US8580299 | VIVUS | Escalating dosing regimen for effecting weight loss and treating obesity |
Jun, 2029
(6 years from now) | |
Drugs and Companies using PHENTERMINE HYDROCHLORIDE; TOPIRAMATE ingredient
Treatment: Use of qsymia (phentermine and topiramate) for weight management, including, but not limited to effecting weight loss, treating obesity, and/or treating overweight
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| EQ 3.75MG BASE;23MG | CAPSULE, EXTENDED RELEASE;ORAL | Prescription |
| EQ 7.5MG BASE;46MG | CAPSULE, EXTENDED RELEASE;ORAL | Prescription |
| EQ 11.25MG BASE;69MG | CAPSULE, EXTENDED RELEASE;ORAL | Prescription |
| EQ 15MG BASE;92MG | CAPSULE, EXTENDED RELEASE;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.